- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Pfizer, Merck rated highly by docs
When asked to rate pharmaceutical companies, physicians most value three attributes: commitment to research and development, credibility and educational orientation, according to Newtown, PA-based Scott-Levin's Pharmaceutical Company Image 2000 study. According to the report, doctors overall ranked Pfizer Inc., New York; Merck & Co. Inc., Whitehouse Station, NJ; and Glaxo Wellcome Inc., Research Triangle Park, NC, as having the strongest commitment to research and development. For the study, Scott-Levin surveyed physicians in 27 specialties, nurse practitioners, physician assistants, HMO medical directors and pharmacists.
When asked to rate pharmaceutical companies, physicians most value three attributes: commitment to research and development, credibility and educational orientation, according to Newtown, PA-based Scott-Levin's Pharmaceutical Company Image 2000 study. According to the report, doctors overall ranked Pfizer Inc., New York; Merck & Co. Inc., Whitehouse Station, NJ; and Glaxo Wellcome Inc., Research Triangle Park, NC, as having the strongest commitment to research and development. For the study, Scott-Levin surveyed physicians in 27 specialties, nurse practitioners, physician assistants, HMO medical directors and pharmacists.
Other results from the research and development portion of the survey:
•Â Bristol-Myers Squibb Co., New York, placed fourth, up from fifth in 1998.
•Â Johnson & Johnson, New Brunswick, NJ, finished fifth, up from sixth in the previous study.
•Â Two companies in the top 15 did not exist in 1998. AstraZeneca, Wilmington, DE, formed by the union of Astra and Zeneca, was ranked ninth. Aventis, the result of the merger between Rhone-Poulenc Rorer and Hoechst Marion Roussel, placed 15th. PR
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
